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Introduction
For children with Juvenile Idiopathic Arthritis (JIA) who
fail to respond to methotrexate, the delay in identifying
the optimal treatment at an early stage of disease can
lead to long-term joint damage. Recent studies indicate
that relevant variants to predict methotrexate response
in JIA are those in 5-aminoimidazole-4-carboxamide
ribonucleotide-transformylase (ATIC), inosine-tripho-
sphate-pyrophosphatase (ITPA) and solute-liquid-
carrier-19A1 (SLC19A1) genes.
Objectives
The purpose of the study was to explore the role of these
candidate genetic factors on methotrexate response in an
Italian cohort of children with JIA.
Methods
Clinical response to methotrexate was evaluated clinical
remission stable for a 6-months period, as ACRPed score
and as change in JADAS score. The most relevant SNPs
for each gene considered were assayed on patients’ DNA.
ITPA activity was measured in patients’ erythrocytes.
Results
69 patients with JIA were analyzed: 52.2% responded to
therapy (ACRPed70 score), while 37.7% reached clinical
remission stable for 6 months. ATIC rs2372536 GG
genotype was associated with improved clinical remission
(adjusted p-value = 0.0090). For ITPA, rs1127354 A variant
was associated with reduced clinical remission: (adjusted
p-value = 0.028); this association was present even for
patients with wild-type ITPA and low ITPA activity.
Conclusion
Genotyping of ATIC rs2372536 and ITPA rs1127354 var-
iants or measuring ITPA activity could be useful to predict
methotrexate response in children with JIA after validation
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